Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine.
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine.
复制标题
BNT162B2 mRNA疫苗六个月后，抗SARS-COV-2免疫反应的概述。
DOI：
10.3390/vaccines10020171
复制
发表时间：
2022-01-22
期刊：
影响因子：
7.8
通讯作者：
Cusi MG
中科院分区：
文献类型：
--
作者：
Gandolfo C;Anichini G;Mugnaini M;Bocchia M;Terrosi C;Sicuranza A;Gori Savellini G;Gozzetti A;Franchi F;Cusi MG
背景资料：我们设计了一项前瞻性研究，旨在监测BNT 162 b2 mRNA疫苗接种后6个月178名医护人员的免疫应答。研究方法：所有受试者的体液免疫反应通过化学发光（CMIA）进行了评价;在60份血清样本中，还测试了基于活病毒的中和试验。此外，在疫苗接种后6个月，在用三聚体SARS-CoV-2刺突蛋白作为抗原再刺激后，通过FACS分析观察来自20名受试者的B-和T-细胞亚群，从而模拟体外再感染。结果：观察到循环IgG水平和中和抗体随时间显著降低。此外，接种后6个月，观察到PBMC体外抗原刺激后的可变T细胞免疫应答。相反，对B细胞反应的分析显示从未转换到转换的记忆B细胞的转变和Th 17细胞的增加。结论：尽管在接种疫苗的受试者中观察到CD 4+和CD 8+免疫应答的变异性以及抗体下降，但与中和抗体的存在相关的转换记忆B细胞和Th 17细胞的增加开启了关于疫苗接种正确时机的辩论。
Background: We have designed a prospective study aiming to monitor the immune response in 178 health care workers six months after BNT162b2 mRNA vaccination. Methods: The humoral immune response of all subjects was evaluated by chemiluminescence (CMIA); in 60 serum samples, a live virus-based neutralization assay was also tested. Moreover, 6 months after vaccination, B- and T-cell subsets from 20 subjects were observed by FACS analysis after restimulation with the trimeric SARS-CoV-2 Spike protein as an antigen, thus mimicking reinfection in vitro. Results: A significant decrease of circulating IgG levels and neutralizing antibodies over time were observed. Moreover, six months after vaccination, a variable T-cell immune response after in vitro antigen stimulation of PBMC was observed. On the contrary, the analysis of B-cell response showed a shift from unswitched to switched memory B-cells and an increase of Th17 cells. Conclusions: Although the variability of the CD4+ and CD8+ immune response and an antibody decline was observed among vaccinated subjects, the increase of switched memory B-cells and Th17 cells, correlating with the presence of neutralizing antibodies, opened the debate on the correct timing of vaccination.
登录
查看更多内容
影响因子：
64.8
作者：
Gaebler C;Wang Z;Lorenzi JCC;Muecksch F;Finkin S;Tokuyama M;Cho A;Jankovic M;Schaefer-Babajew D;Oliveira TY;Cipolla M;Viant C;Barnes CO;Bram Y;Breton G;Hägglöf T;Mendoza P;Hurley A;Turroja M;Gordon K;Millard KG;Ramos V;Schmidt F;Weisblum Y;Jha D;Tankelevich M;Martinez-Delgado G;Yee J;Patel R;Dizon J;Unson-O'Brien C;Shimeliovich I;Robbiani DF;Zhao Z;Gazumyan A;Schwartz RE;Hatziioannou T;Bjorkman PJ;Mehandru S;Bieniasz PD;Caskey M;Nussenzweig MC
通讯作者：
Nussenzweig MC
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1056/nejmoa2110345
发表时间：
2021-11-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Thomas SJ;Moreira ED Jr;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Polack FP;Zerbini C;Bailey R;Swanson KA;Xu X;Roychoudhury S;Koury K;Bouguermouh S;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Yang Q;Liberator P;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Gruber WC;Jansen KU;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1016/s0140-6736(21)02183-8
发表时间：
2021-10-16
期刊：
Lancet (London, England)
影响因子：
--
作者：
Tartof SY;Slezak JM;Fischer H;Hong V;Ackerson BK;Ranasinghe ON;Frankland TB;Ogun OA;Zamparo JM;Gray S;Valluri SR;Pan K;Angulo FJ;Jodar L;McLaughlin JM
通讯作者：
McLaughlin JM
影响因子：
8.1
作者：
Liang, Decui;Wang, Mingwei;Xu, Zeshui
通讯作者：
Xu, Zeshui